[Cisplatin ototoxicity: series of cases].
OBJECTIVE
To evaluate the clinic and audiometric evolution of individuals who underwent chemotherapy with cisplatin.


METHODS
Four volunteers, all women, between 38 and 69 years of age were descriptively evaluated. All did otorinolaryngoiatric exam and audiometric evaluation with tonal and speech audiometric and impedance tests before and after treatment with cisplatin. In addition, all were subjectively evaluated pre- and post-chemotherapy by a questionnaire.


RESULTS
One volunteer did not present auditory disorders. Three volunteers presented bilateral hearing loss, mild to moderate in 6 kHz and 8 kHz frequencies, after chemotherapy with cisplatin. All volunteers who developed hearing loss after treatment also presented tinnitus.


CONCLUSIONS
Since cisplatin is considered ototoxic, all individuals undergoing chemotherapy with this drug must be submitted to audiometric monitoring for early diagnosis of a hearing loss.
Mota
Luiz Alberto Alves
LA
Hospital Universitário Oswaldo Cruz. luizmota10@hotmail.com
Melo
Marília Silvino Iglésias
MS
Santos
Maria Heloísa Pedrosa
MH
de Albuquerque
Kátia Maria Gomes
KM
Tavares
Cristiana de Lima
Cde L
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001299:Audiometry; D002945:Cisplatin / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006312:Hearing Loss, Bilateral / Q000139:chemically induced / Q000503:physiopathology; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D012016:Reference Values; D013997:Time Factors; D014012:Tinnitus / Q000139:chemically induced / Q000503:physiopathology; D014594:Uterine Neoplasms / Q000188:drug therapy*